Koltai Katalin, Kesmarky Gabor, Feher Gergely, Tibold Antal, Toth Kalman
First Department of Medicine, University of Pecs, Pecs 7624, Hungary.
Hospital of Szigetvar, Szigetvar 7900, Hungary.
Int J Mol Sci. 2017 Aug 18;18(8):1803. doi: 10.3390/ijms18081803.
Platelets play a fundamental role in normal hemostasis, while their inherited or acquired dysfunctions are involved in a variety of bleeding disorders or thrombotic events. Several laboratory methodologies or point-of-care testing methods are currently available for clinical and experimental settings. These methods describe different aspects of platelet function based on platelet aggregation, platelet adhesion, the viscoelastic properties during clot formation, the evaluation of thromboxane metabolism or certain flow cytometry techniques. Platelet aggregometry is applied in different clinical settings as monitoring response to antiplatelet therapies, the assessment of perioperative bleeding risk, the diagnosis of inherited bleeding disorders or in transfusion medicine. The rationale for platelet function-driven antiplatelet therapy was based on the result of several studies on patients undergoing percutaneous coronary intervention (PCI), where an association between high platelet reactivity despite P2Y12 inhibition and ischemic events as stent thrombosis or cardiovascular death was found. However, recent large scale randomized, controlled trials have consistently failed to demonstrate a benefit of personalised antiplatelet therapy based on platelet function testing.
血小板在正常止血过程中发挥着重要作用,而其遗传性或获得性功能障碍则与多种出血性疾病或血栓形成事件有关。目前有几种实验室方法或即时检测方法可用于临床和实验环境。这些方法基于血小板聚集、血小板黏附、凝血形成过程中的黏弹性特性、血栓素代谢评估或某些流式细胞术技术,描述了血小板功能的不同方面。血小板聚集测定法应用于不同的临床环境,如监测抗血小板治疗的反应、评估围手术期出血风险、诊断遗传性出血性疾病或用于输血医学。血小板功能驱动的抗血小板治疗的理论依据基于多项针对接受经皮冠状动脉介入治疗(PCI)患者的研究结果,这些研究发现,尽管使用了P2Y12抑制剂,但高血小板反应性与缺血事件(如支架血栓形成或心血管死亡)之间存在关联。然而,最近的大规模随机对照试验一直未能证明基于血小板功能检测的个性化抗血小板治疗有任何益处。